Abstract: Mechanical refrigeration system includes a compression device. The compression device has a pair of dual-action cylinders connected together by a movable rod thereof. A first cylinder acts as an element for compressing coolant fluid, for which purpose the rod is moved through the second cylinder, fed by a pressurised fluid that allows the flow of coolant fluid in the first cylinder and the flow of pressurised fluid of the second cylinder at the outlet of both devices to be constant, thus configuring a completely autonomous device that does not need electricity or any type of fuel.

Abstract: A method for calorimetry includes providing a sample to a test chamber and applying heat to the test chamber with the sample provided therein, the heat being applied at a known heat rate. In a synchronized manner with respect to applying heat to the test chamber, transmission of light through plural Nano Hole Array (NHA) sensors coupled to the test chamber is measured to obtain a series of extraordinary optical transmission (EOT) measurements. A calorimetry measurement is calculated as a function of the heat rate and the series of EOT measurements, the calorimetry measurement being indicative of energy released as a result of the sample undergoing a change during the application of heat to the test chamber. Samples, including fluids and solids, can be transferred into the test chamber by a pump or other suitable means. Example test chambers include a microchannel injection cell and a co-flow reactor microchannel.

Abstract: The present invention relates to a water-insoluble controlled-release pattern recognition receptor agonist (“PRRA”) for use in the treatment of a cell-proliferation disorder, wherein the water-insoluble controlled-release PRRA is administered by intra-tissue administration, and wherein the protein levels of at least one cytokine selected from the group consisting of IL-6, CCL2 and EL-10 in plasma has a more than 10-fold lower maximum protein level within 24 hours compared to an equivalent molar dose of the corresponding free PRRA upon intra/tissue administration; and to related aspects.

Abstract: The present invention relates to a water-insoluble controlled-release pattern recognition receptor agonist (“PRRA”) or its pharmaceutically acceptable salt or a pharmaceutical composition comprising such water-insoluble controlled-release PRRA or its pharmaceutical acceptable salt for use in the treatment of a cell-proliferation disorder, wherein the water-insoluble controlled-release PRRA, its pharmaceutically acceptable salt or the pharmaceutical composition is administered by intra-tissue administration, and wherein such intra-tissue administration results in local inflammation; and to related aspects.

Abstract: The present invention relates to a water-insoluble controlled-release pattern recognition receptor agonist (“PRRA”) or its pharmaceutically acceptable salt or a pharmaceutical composition comprising such water-insoluble controlled-release PRRA or its pharmaceutical acceptable salt for use in the treatment of a cell-proliferation disorder, wherein the water-insoluble controlled-release PRRA, its pharmaceutically acceptable salt or the pharmaceutical composition is administered by intra-tissue administration, and wherein at least 25% of the amount of PRRA remains local in such tissue 3 days after administration; and to related aspects.

Abstract: The invention relates to the special configuration of a compression device of a refrigeration system and to its actuation method. The device consists of a pair of dual-action cylinders (8-9) connected together by means of the movable rod (11) thereof, such that the first cylinder (8) acts as an element for compressing coolant fluid, for which purpose the rod is moved through the second cylinder (9), being fed by a pressurised fluid which, by means of a series of branches and valves controlled using limit switches of the rod (11), allow the flow of coolant fluid in the first cylinder and the flow of pressurised fluid of the second cylinder at the outlet of both devices to be constant. Thus, a completely autonomous device that does not need electricity or any type of fuel is obtained.

Abstract: The invention relates to an electric motor in which the coil can be configured according to the specific needs of each case, so as to be able to play with the torque/speed ratio that it can provide at any particular moment. For this purpose, each winding of the coil that is used in the motor is divided into a predetermined number of wires (100) having the same cross-section and length, so that said wires are grouped together and insulated from one another defining a specific predetermined number of groups, the ends or poles (Al, A2, A3 . . . , U1, U2, U3, . . . ) of each group being connected to switching means, via which the wires (100) are selectively connected in multiple configurations, either all in parallel, all in series or in various intermediate combinations, thus obtaining an equivalent coil in which the equivalent cross-section and length can vary according to the connection configuration of the wires (100).

Abstract: The invention provides methods and compositions for identifying a modulator of CCRL2 and chemerin. The present invention also provides methods and compositions for treating an inflammatory disease by administering a compound that modulates the interaction of CCRL2 with chemerin.

Abstract: Methods are provided for regulating adipogenesis and metabolic function in adipocytes by modulating the activity of chemokine-like receptor 1 (CMKLR1). Exemplary agents include those that modulate binding of CMKLR1 to a cognate ligand (e.g., chemerin), those that modulate signaling from CMKLR1, and those that modulate expression of either CMKLR1 or its cognate ligand in target cells. Methods are also provided for screening for agents that find use in regulating fat accumulation in a subject.